Key insights
- BioNTech's Q1 earnings are expected to show a significant drop in revenue due to declining COVID-19 vaccine sales. Investors are focused on the progress of its oncology pipeline, particularly the HER2-targeted antibody-drug conjugate and pumitamig for lung cancer. Analyst ratings are generally positive, but the company faces challenges in transitioning to oncology and managing a leadership change. The negative earnings profile and uncertain transition contribute to a slightly bearish outlook.
BioNTech SE reports first-quarter results before the bell Tuesday, with investors focused on whether the German biotech’s oncology pivot can offset a sharp drop in COVID-19 vaccine revenue as losses widen and a leadership transition looms.
Analysts expect the company to post a loss of €2.15 per share on revenue of €185.6 million, according to consensus estimates. That would mark a steep sequential decline from the prior quarter, when BioNTech reported a loss of €1.25 per share on revenue of €907.4 million—a result that beat expectations by nearly 19% on the top line. The expected 79% revenue drop reflects the ongoing collapse in COVID vaccine demand that has forced the company to reinvent itself around cancer therapeutics.
Analysts rate the stock a Buy, with a mean price target of $130.94 implying 34% upside from Friday’s close of $97.54. Shares have traded in a wide range over the past year, from a low of $79.52 to a high of $124.00, and currently sit near the middle of that band as the market weighs the company’s $24.7 billion valuation against a negative earnings profile and uncertain transition.
EPS estimates have risen 5.2% over the past 60 days, suggesting analysts see a path to improving profitability, while revenue estimates have tumbled 56% over the same period, underscoring the magnitude of the post-pandemic revenue reset. Both estimates have remained flat over the past week.
What Investors Are Watching
The key question is execution in oncology. BofA Securities highlighted positive Phase 2 data for BioNTech’s HER2-targeted antibody-drug conjugate in endometrial cancer, with a 47.9% response rate that compares favorably to chemotherapy. The firm called the data "a stepping stone" for building commercial infrastructure ahead of a planned 2026 regulatory filing. H.C. Wainwright pointed to competitive Phase 2 results for pumitamig, a PD-L1xVEGF bispecific, in first-line lung cancer, which is now advancing through seven Phase 3 trials including head-to-head studies against Merck’s Keytruda.
Investors will also parse management’s commentary on sequential revenue trends and the sustainability of COVID vaccine sales. The company guided 2026 full-year revenue to €2.0–€2.3 billion, down from €2.9 billion in 2025, putting pressure on the oncology pipeline to deliver near-term commercial wins.
Leadership uncertainty adds another layer of risk. Co-founders and current executives Ugur Sahin and Özlem Türeci plan to depart by year-end to launch a new mRNA-focused venture, with BioNTech contributing select mRNA rights in exchange for a minority stake. Leerink Partners noted that a strong CEO appointment "could drive upside," but uncertainty over succession and strategic focus has weighed on sentiment.
Finally, regulatory headwinds for COVID vaccines remain a wildcard. Leerink flagged that BioNTech and partner Pfizer were unable to enroll a Phase 3 booster study required by the FDA, raising questions about the durability of the company’s vaccine franchise.
BioNTech’s gross margin of 78.7% and €16.7 billion cash position provide a cushion, but with losses projected to persist, the quarter will test whether the company’s oncology gamble is gaining traction—or whether the post-COVID reckoning has further to run.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.